Bottomline, there is no accurate way to do this yet
Such rigorous evaluations involved reviewing extensive clinical data, ensuring that the medication could provide substantial benefits for individuals struggling with obesity
Nielsen, S., Mller, N., Christiansen, J
These relaxing, pampering experiences are designed to leave you feeling rejuvenated while achieving real, lasting results
In a Phase 2 obesity trial of retatrutide published in the New England Journal of Medicine in 2023, nausea, diarrhea, vomiting and constipation were cited as the most common adverse events, with higher doses associated with more severe problems
Current clinical data has not highlighted a significant, consistent difference in the onset timeline between sexes